Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2020)
Neoadjuvant chemoradiotherapy in rectal cancer. Are there new drug combinations on the horizon? memo
Frédéric Witte, W. Hilbe, E. Müldür (2020)
Four lines of immunochemotherapy combinations in a young patient with an aggressive metastatic colorectal cancermemo - Magazine of European Medical Oncology
(2020)
Four lines of immunochemotherapycombinations inayoungpatientwithanaggressive metastaticcolorectalcancer. memo
F. Lunger, G. Peros (2020)
Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancermemo - Magazine of European Medical Oncology
Amir Zaid, E. Aboelnaga, A. Halim, M. Abdelkhalek, S. Elbalka, M. Zuhdy, Ahmed Fareed, E. Ibrahim, Hosam Halim, I. Metwally (2020)
Rectal cancer among younger Egyptian patients—clinico-pathological features and oncologic outcomes: A single institution experiencememo - Magazine of European Medical Oncology, 13
Andreas Reichinger, H. Rumpold (2020)
Circulating tumour DNA-guided adjuvant chemotherapy in colorectal carcinomamemo - Magazine of European Medical Oncology, 13
C. Arnold, J. Mangesius, R. Jäger, U. Ganswindt (2020)
Neoadjuvant chemoradiotherapy in rectal cancermemo - Magazine of European Medical Oncology
editorial memo (2020) 13:251–252 https://doi.org/10.1007/s12254-020-00631-y Rectal cancer: latest developments and innovative new treatment concepts Arno Amann © Springer-Verlag GmbH Austria, part of Springer Nature 2020 In this special issue of the Magazine of European combinations in neoadjuvant chemoradiotherapy Medical Oncology (MEMO), a multidisciplinary team concerning rectal cancer are discussed. Three inno- of experts summarizes and discusses recent develop- vative and promising new strategies to improve rectal ments and interesting results in rectum carcinoma, cancer treatment, the total neoadjuvant therapy, short from a rising incidence in a young patient cohort to course radiotherapy and the implementation of im- neoadjuvant, palliative and adjuvant treatment pro- mune checkpoint inhibitors seem to be the way to go tocols. Especially up-front therapy before surgery has in the future. been the field within the multimodal treatment of this In the short review by Reichinger et al. [4], a novel cancer entity with the most promising and interesting form of guided adjuvant treatment in colorectal can- developments over the last year, raising the question cer is discussed by analysing circulating tumour DNA of whether surgery is always needed or whether an (ctDNA) as an indicator of residual disease after organ-preserving concept will be the way to
memo - Magazine of European Medical Oncology – Springer Journals
Published: Sep 1, 2020
Keywords: oncology; medicine/public health, general
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.